MDM2 and pulmonary arterial hypertension: Serdemetan, an MDM2 inhibitor, mitigates experimental pulmonary hypertension (PH) in mice, partially through the inhibition of MDM2-mediated ubiquitination of angiotensin-converting enzyme 2 (ACE2) and thus rectified ACE2 expression [72].